Park Avenue Securities LLC Has $433,000 Stake in Bruker Co. (NASDAQ:BRKR)

Park Avenue Securities LLC reduced its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 2.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,395 shares of the medical research company’s stock after selling 181 shares during the period. Park Avenue Securities LLC’s holdings in Bruker were worth $433,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after purchasing an additional 2,521,904 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Bruker in the 2nd quarter worth approximately $36,472,000. Point72 DIFC Ltd raised its stake in shares of Bruker by 4,875.9% during the 3rd quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company’s stock worth $32,470,000 after purchasing an additional 460,722 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Bruker by 1,933.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock valued at $28,331,000 after acquiring an additional 390,057 shares during the last quarter. Finally, State Street Corp increased its position in Bruker by 9.6% in the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock worth $250,501,000 after buying an additional 318,808 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Stock Performance

Shares of NASDAQ:BRKR opened at $58.19 on Friday. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The company has a market cap of $8.82 billion, a price-to-earnings ratio of 27.98, a price-to-earnings-growth ratio of 3.51 and a beta of 1.17. Bruker Co. has a 12 month low of $48.07 and a 12 month high of $94.86. The company has a 50-day moving average price of $58.04 and a 200-day moving average price of $61.58.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. During the same quarter last year, the business posted $0.74 EPS. The company’s quarterly revenue was up 16.4% compared to the same quarter last year. As a group, equities analysts anticipate that Bruker Co. will post 2.4 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 annualized dividend and a yield of 0.34%. Bruker’s dividend payout ratio (DPR) is presently 9.62%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. TD Cowen cut their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Citigroup decreased their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Bank of America increased their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Finally, UBS Group began coverage on shares of Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price on the stock. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $74.45.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 28.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.